Evotec Wins $2.9 Million Gates Grant for Stem Cell Safety Testing
Evotec has won a new $2.9 million grant from the Gates Foundation to keep running its human stem cell platform that flags fetal development risks in new drug candidates. The award extends a project that began in 2023 for three more years.
The grant is small. The bottleneck it attacks isn't. A safety signal that arrives before a trial is worth more than a bigger one that arrives after, and that's the whole bet behind screening 5,000 compounds before anyone doses a patient.
Evotec SE announced on Monday, November 16, that it has been awarded a new $2.9 million grant by the Gates Foundation to support continued use of its human stem cell platform for spotting potential safety risks to fetal development in new drug candidates. The funding extends a project that began in 2023 for a further three years.
The platform works from human induced pluripotent stem cells, adult cells reprogrammed back to a stem cell state, combined with industrial-scale screening. The cells model aspects of human development in a dish, so researchers can test whether a compound is likely to interfere with fetal development long before the drug reaches a clinical trial, where that kind of risk is hardest and most expensive to find.
These methods sit inside a broader shift regulators call New Approach Methodologies: human-relevant lab systems meant to give earlier, better-informed decisions about which drug candidates deserve to advance. Evotec says the point isn't to replace clinical testing. It's to kill weak candidates earlier, while killing them is still cheap, and to give global health researchers the same early warning the platform provides.
The first three years produced the evidence this extension is buying. Over the initial collaboration, more than 5,000 compounds were screened across nine research programs run by Gates Foundation grantees, a throughput that shows the system works at the scale drug discovery actually operates at, not just as a demonstration. The platform's development and validation are described in a recent preprint posted to bioRxiv.
Dr. Joanna Holbrook, Evotec's chief scientific officer, said the continued collaboration underscores the company's capabilities in advanced human cell-based drug discovery technologies. The company, based in Hamburg, trades on Nasdaq under the ticker EVO and on the Frankfurt Prime Standard under EVT.
The money is modest next to a clinical program, and that's the point worth keeping. A $2.9 million screening grant doesn't develop a drug. It decides, 5,000 compounds at a time, which drugs are worth developing at all, and it keeps that decision available to global health programs that can't build the platform themselves. The next three years will show whether the screening record holds as the compound count climbs.
The fetal safety question is one of drug development's oldest blind spots. Compounds are routinely screened for general toxicity, but developmental toxicity is harder to model, because the system being protected doesn't exist yet in the patient taking the drug. Animal studies have carried that load for decades, with well-documented limits in how far their results translate to human development. A human cell system that flags risk earlier speaks directly to that gap.
For the Gates Foundation, the grant buys access, not ownership. The nine grantee programs that used the platform in the first phase are global health projects, the kind of research where a late-stage safety failure doesn't just cost money, it ends a program that may not have a second funder. Keeping the screening open for three more years keeps that early warning in place for the next round of candidates moving through those pipelines.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.